Evogene Ltd. — Foreign Filer Report 2017

Jun 6, 2017

6-K 1 zk1720090.htm 6-K Licensed to: ZKG Document created using EDGARfilings PROfile 4.2.1.0 Copyright 1995 - 2017 Summit Financial Printing, LLC. All rights reserved.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2017

Commission File Number: 001-36187

EVOGENE LTD.

(Translation of Registrant's Name into English)

13 Gad Feinstein Street

Park Rehovot P.O.B 2100

Rehovot 7612002 Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

CONTENTS

The annual general meeting of shareholders (the " Meeting ") of Evogene Ltd. (" Evogene ") will be held at Evogene's offices, located at 13 Gad Feinstein Street, Park Rehovot, Rehovot, Israel, on Tuesday, July 18, 2017 at 3:00 p.m., Israel time. In connection with the Meeting, Evogene hereby furnishes the following documents:

Exhibit 99.1	Notice of the Meeting.
Exhibit 99.2 Exhibit 99.3	Proxy Statement for the Meeting. Form of Proxy Card for the Meeting.

The foregoing exhibits are available on the Company's website at investors.evogene.com/sec-filings.

This Form 6-K is incorporated by reference into the Company's registration statements on Form S-8 (File Nos. 333-193788, 333-201443 and 333-203856).

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: June 6, 2017 EVOGENE LTD. (Registrant) By: /s/ Alex Taskar Name: Alex Taskar Title: Chief Financial Officer

3

EXHIBIT INDEX

EXHIBIT NO.	DESCRIPTION
99.1	Notice of the annual general meeting of shareholders of Evogene Ltd. (the " Meeting ") to be held on July 18, 2017.
99.2	Proxy Statement for the Meeting.
99.3	Form of Proxy Card for the Meeting.

4